

The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada: Supplementary material S1

Model structure

A dynamic compartmental mathematical model of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) was developed in Montréal (Canada), the nexus of the epidemic in the province of Québec. The model is stratified by sex and considers three distinct but overlapping dynamics: 1) HCV transmission, 2) incarceration, and 3) injection behaviors. The model has an open population and is deterministic in nature. Stochasticity was not included because HCV prevalence is high among the PWID population and elimination is defined in terms of public health targets, which means that incidence cannot be null (Leclerc et al., 2018; Courtemanche et al., 2016; Poulin et al., 2007).

People are susceptible to HCV when entering the population at a rate θ chosen to fit PWID population size estimates in 2003 and 2010 (Leclerc et al., 2014). Individuals who enter the model are active PWID (i.e. current injection) and have never been incarcerated. PWID either leave the model by all-cause (μ) or liver-related (μ_1) mortality at advanced disease stages ($C_{F3-4}(t)$, $T_{F3-4}(t)$). Individuals who are active PWID, and those recently released from prison have an increased risk of death (Π). People who are on treatment can only die of other mortality causes, excluding HCV-related deaths, during that short period.

HCV transmission dynamics

The model, based on previous work by Stone et al. (2017), considers HCV's natural history as well as the HCV treatment and care cascade (Figure S1.1). Individuals start in the susceptible compartment ($S(t)$). They can then acquire HCV and transition to the acute stage ($A(t)$) depending on a time-varying force of infection $\lambda(t)$. The force of infection represents the annual per capita rate of HCV acquisition and is a function of chronic prevalence among injecting contacts, mixing, incarceration status, and coverage of interventions (needle and syringe programs – NSP). For instance, currently incarcerated people can only be infected by other incarcerated individuals because their only effective contacts occur within that group. Further details and assumptions on mixing are provided below.

Once individuals acquire HCV infection, they either spontaneously clear with at a probability of α_{ab} after 6 months, or progress to early chronic infection ($C_{F0-2}(t)$). Those who clear the infection become susceptible to re-infection but are antibody positive to HCV ($S_{ab+}(t)$). They can then be re-infected




Figure S1.1: Hepatitis C (HCV) natural history and cascade of care. The model is open, and people initiate injection as susceptible ($S(t)$) at a rate θ . Upon an effective contact, they become acutely infected ($A(t)$) at a time-dependent force of infection $\lambda(t)$. People spontaneously clear the infection after six months at a probability α_{ab} and become susceptible but antibody positive ($S_{ab+}(t)$). Otherwise, they become chronically infected ($C_{F0-2}(t)$) and progress in fibrosis stages until late HCV infection ($C_{F3-4}(t)$), where they can die of liver-related mortality μ_1 . Chronically infected people can be diagnosed ($\mathbf{Dx}_{F0-2}(t)$, $\mathbf{Dx}_{F3-4}(t)$) without regards to disease stage at a rate $\tau(t)$ and then linked to treatment ($\mathbf{Tx}(t)$) at a time varying rate that depends on fibrosis stage ($\sigma_{F0-2}(t)$, $\sigma_{F3-4}(t)$). Treatment either leads to failure or sustained virologic response and people become susceptible but antibody positive. People who spontaneously cleared or were cured of the disease are susceptible to re-infection with HCV (A_{ab+}) at the same force of infection $\lambda(t)$.

($A_{ab+}(t)$) at the same force of infection $\lambda(t)$ as that of primary infection. This is a conservative assumption that can be justified by the limited evidence regarding immunity conferred by past exposures to the virus. Upon re-infection, individuals can still spontaneously clear at the same probability (α_{ab}) after six months. Evidence concerning an enhanced clearance rate at six months in people who previously cleared the infection is still scarce, yet it was recently suggested that it could be higher, but with important uncertainty concerning the magnitude of the effect size (Sacks-Davis et al., 2015).

People with chronic HCV infection progress through fibrosis stages at a rate of ξ , which represents the number of fibrosis units gained on the metavir scale per year (Erman et al., 2018). As a simplifying assumption, fibrosis was dichotomized between early ($C_{F0-2}(t)$) and late ($C_{F3-4}(t)$) stages. Only people with chronic infection are allowed to be diagnosed and treated, which is in line with current guidelines (Shah et al., 2018). Individuals are first tested for HCV at a time-dependent rate $\tau_p(t)$, which

also varies by incarceration status. Only diagnosed individuals ($D_{x_{F0-2}}(t)$, $D_{x_{F3-4}}(t)$) can be treated at a time varying rate $\sigma_p(t)$, which also varies by incarceration status. Because of the reluctance to treat PWID in the PEG-IFN era, a treatment rate of zero was assumed before the widespread arrival of DAA in 2015. Between 2015-2018, only people with late chronic infection ($D_{x_{F3-4}}(t)$) are eligible for DAA therapy. In line with the most recent Canadian guidelines on HCV management, it was conservatively assumed that people with early chronic infection ($D_{x_{F0-2}}(t)$) are eligible for treatment from 2018, but treated at a rate which is half that of late stage infection. As done in previous studies and reflecting the paucity of the data on treatment initiation rate among active PWID, the treatment rates in the community ($\sigma_c(t)$) were fixed as follows (Stone et al., 2017):

$$\sigma_c^{F0-2}(t) = \begin{cases} 0 & t < 2018 \\ 0.5\sigma_c^{F3-4}(t) & t \geq 2018 \end{cases}$$

$$\sigma_c^{F3-4}(t) = \begin{cases} 0 & t < 2015 \\ 0.01 & t \geq 2015 \end{cases}$$

Treatment ($T(t)$) has two distinct outcomes: sustained virologic

response (SVR) or failure (Stone et al., 2017). People on treatment achieve SVR at a probability α_{svr} , after an average treatment duration of 12 weeks. Following SVR, people treated successfully remain antibody positive for the rest of their life ($S_{ab+}(t)$). As there is currently no convincing evidence of DAA-treatment conferred immunity, treated individuals are susceptible to reinfection at the standard force of infection $\lambda(t)$. People who are re-infected transition to the acutely infected but antibody positive compartment ($A_{ab+}(t)$). Those who do not achieve SVR return to the diagnosed stages after the duration of treatment (d_t , either $D_{x_{F0-2}}(t)$ or $D_{x_{F3-4}}(t)$, proportionally to the number of individuals treated from each stage (p_{F0-2} , p_{F3-4}). As such, people with re-infections are eligible for re-treatment at the same rate as people with primary infections. This last assumption is justified by the availability of pan-genotypic drugs, which allow treatment of individuals with recurrent infection with little concern for drug resistance (Feld and Foster, 2016). The full system of ordinary differential equations is presented below for individual with sex g , incarceration status p and injection status i .

$$\begin{aligned} \frac{dS_{gpi}(t)}{dt} &= \theta(t) - (\lambda_{gpi}(t) + \mu)S_{gpi}(t) \\ \frac{dS_{gpi}^{ab+}(t)}{dt} &= \frac{\alpha}{d_A} (A_{gpi}(t) + A_{gpi}^{ab+}(t)) + \frac{\alpha_{svr}}{d_T} T x_{gpi}(t) - (\lambda_{gpi}(t) + \mu)S_{gpi}^{ab+}(t) \\ \frac{dA_{gpi}(t)}{dt} &= \lambda_{gpi}(t)S_{gpi}(t) - \left(\frac{1}{d_A} + \mu\right)A_{gpi}(t) \\ \frac{dA_{gpi}^{ab+}(t)}{dt} &= \lambda_{gpi}(t)S_{gpi}^{ab+}(t) - \left(\frac{1}{d_A} + \mu\right)A_{gpi}^{ab+}(t) \\ \frac{dC_{gpi}^{F0-2}(t)}{dt} &= \frac{(1-\alpha)}{d_A} [A_{gpi}(t) + A_{gpi}^{ab+}(t)] - (\xi + \tau_p(t) + \mu)C_{gpi}^{F0-2}(t) \\ \frac{dC_{gpi}^{F3-4}(t)}{dt} &= \xi C_{gpi}^{F0-2}(t) - (\tau_p(t) + \mu + \mu_1)C_{gpi}^{F3-4}(t) \\ \frac{dD_{x_{gpi}^{F0-2}}(t)}{dt} &= \tau_p(t)C_{gpi}^{F0-2}(t) + \left(\frac{p_{F0-2}(1-\alpha_{svr})}{d_T}\right)T x_{gpi}(t) - (\xi + \sigma_p^{F0-2}(t) + \mu)D_{x_{gpi}^{F0-2}}(t) \\ \frac{dD_{x_{gpi}^{F3-4}}(t)}{dt} &= \tau_p(t)C_{gpi}^{F3-4}(t) + \left(\frac{p_{F3-4}(1-\alpha_{svr})}{d_T}\right)T x_{gpi}(t) + \xi D_{x_{gpi}^{F0-2}}(t) - (\sigma_p^{F3-4}(t) + \mu + \mu_1)D_{x_{gpi}^{F3-4}}(t) \\ \frac{dT x_{gpi}(t)}{dt} &= \sigma_p^{F0-2}(t)D_{x_{gpi}^{F0-2}}(t) + \sigma_p^{F3-4}(t)D_{x_{gpi}^{F3-4}}(t) - \frac{1}{d_T}T x_{gpi}(t) \end{aligned} \quad (1)$$

Force of infection and mixing patterns

Force of infection

The force of infection is the per capita rate at which individuals acquire HCV and depends on multiple factors. First, it is a function of HCV prevalence (chronic and acute cases) among injecting contacts. This, in turns, depends on the characteristics of the injecting contacts and is parameterized using mixing matrices. Second, the force of infection is influenced by the availability of sterile injecting materials, which varies with respect to time. Third, the force of infection varies by setting.

For instance, it is lower during the incarceration period, but elevated upon the short period following release from prison. Specifically, the force of infection is the product between the mixing matrix and the element-wise multiplication of the rate ratio and prevalence vectors. For an individual of sex g , with the incarceration and injection statuses p and i , respectively, the force of infection is the following.

$$\lambda_{gpi}(t) = \beta \left(1 - \left(\text{cov}_p(t)(1 - \text{eff})\right)\right) (m_{gpi} \times r r_{gpi} p_{gpi}(t)) \quad (2)$$

Where β is the baseline transmission rate; $cov_p(t)$ is the coverage of NSP, calculated from SurvUDI data (Leclerc et al., 2018) as the complement of the proportion of injections performed with previously used needles and syringes (coverage is assumed to be null in prison); eff is the effectiveness of NSP programs as estimated from a recent meta-analysis (Platt et al., 2017); m_{gpi} is a vector of mixing per individual category (further details on the mixing matrix are provided below); rr_{gpi} is a vector of rate ratios for HCV transmission; and $p_{gpi}(t)$ is the prevalence vector for groups that varies with time and is weighted by the rate ratio vector to allow for increased or decreased risk of acquisition and transmission.

Mixing patterns

The mixing matrix considers how contact patterns are structured according to incarceration \mathbf{M}_p , injection status \mathbf{M}_i , and sex \mathbf{M}_g . The full mixing matrix \mathbf{M} is developed from the Kronecker product of smaller mixing matrices. This method consists of multiplying the elements of a matrix with another matrix. The complete contact matrix can be defined as the following, where the mixing probabilities p_{jk} , i_{jk} and g_{jk} , are defined in sections below.

$$\begin{aligned} \mathbf{M} &= \mathbf{M}_p \otimes \mathbf{M}_g \otimes \mathbf{M}_i \\ &= \begin{bmatrix} p_{11} & p_{12} & p_{13} & p_{14} \\ p_{21} & p_{22} & p_{23} & p_{24} \\ p_{31} & p_{32} & p_{33} & p_{34} \\ p_{41} & p_{42} & p_{43} & p_{44} \end{bmatrix} \otimes \begin{bmatrix} g_{11} & g_{12} \\ g_{21} & g_{22} \end{bmatrix} \otimes \begin{bmatrix} i_{11} & i_{12} & i_{13} \\ i_{21} & i_{22} & i_{23} \\ i_{31} & i_{32} & i_{33} \end{bmatrix} \\ &= \begin{bmatrix} p_{11}g_{11}i_{11} & p_{11}g_{11}i_{12} & \cdots & p_{14}g_{12}i_{13} \\ p_{11}g_{11}i_{21} & p_{11}g_{11}i_{22} & \cdots & p_{14}g_{12}i_{23} \\ \vdots & \vdots & \ddots & \vdots \\ p_{41}g_{21}i_{31} & p_{41}g_{21}i_{32} & \cdots & p_{44}g_{22}i_{33} \end{bmatrix} \end{aligned}$$

Incarceration

The contact matrix for incarceration has dimensions 4×4 , the first of which corresponds to the individual's incarceration status and the second to the incarceration status of the contact. On each dimension, elements are 1) never incarcerated, 2) currently incarcerated, 3) recently released, and 4) previously released. Such that, p_{13} would represent the mixing pattern between a never incarcerated person and a person recently released. There is important uncertainty regarding mixing of individuals according to their incarceration status. Specifically, this uncertainty was taken into account with a parameter that varied mixing between proportional and assortative. In the first case, mixing occurs randomly according to the proportion of the population in each category. In the second case, mixing occurs strictly between people of the same category (i.e. like-with-like). The degree of assortative mixing is defined by the parameter $mix_p \in [0, 1]$ and the final mixing matrix is:

$$\mathbf{M}_p = (1 - mix_p)\mathbf{M}_{prop} + mix_p\mathbf{M}_{assor}$$

Where, \mathbf{M}_{prop} is the contact matrix according to the relative presence of individuals in the community. It was assumed that no effective contact could occur between people in the community

and incarcerated people. This is conceptualized as the null values on line and row 2, except for contacts between inmates. The matrix \mathbf{M}_{assor} is perfectly assortative (i.e., identity matrix).

$$\mathbf{M}_{prop} = \begin{bmatrix} p_{11} & 0 & p_{13} & a_{14} \\ 0 & 1 & 0 & 0 \\ p_{31} & 0 & p_{33} & p_{34} \\ p_{41} & 0 & p_{43} & p_{44} \end{bmatrix}$$

$$\mathbf{M}_{assor} = \begin{bmatrix} 1 & 0 & 0 & 0 \\ 0 & 1 & 0 & 0 \\ 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 1 \end{bmatrix}$$

Injection

The mixing matrix by injection status (\mathbf{M}_i) is of format 3×3 , and its structure is similar to mixing by incarceration status. On each dimension, the elements are 1) active PWID, 2) on OAT, 3) ex-PWID. The degree of assortative mixing was defined as mix_i , and, as before, the complete mixing matrix \mathbf{M}_i .

$$\mathbf{M}_i = (1 - mix_i)\mathbf{M}'_{prop} + mix_i\mathbf{M}'_{assor}$$

Where \mathbf{M}'_{prop} is the proportional mixing matrix, and \mathbf{M}'_{assor} the assortative setting. It is assumed that PWID can only have contacts with other PWID or people on OAT. Hence, ex-PWID do not have injecting behaviors putting them at risk of acquiring or transmitting HCV such that the mixing matrices are

$$\mathbf{M}'_{prop} = \begin{bmatrix} i_{11} & i_{12} & 0 \\ i_{21} & i_{22} & 0 \\ 0 & 0 & 0 \end{bmatrix}$$

$$\mathbf{M}'_{assor} = \begin{bmatrix} 1 & 0 & 0 \\ 0 & 1 & 0 \\ 0 & 0 & 0 \end{bmatrix}$$

Sex

Finally, the specification of the overall mixing matrix is completed by considering sex. Sex-based contact pattern data is scarce for injection drug use (IDU), as it is difficult to empirically measure such behaviours. A study of contacts between PWID according to gender, age and race in Baltimore found mixing to be slightly disassortative with respect to gender for females and assortative for male. The mixing matrix for sex was built by using contact data of PWID according to gender from Smith et al. (2016) as it represents the best available evidence for sex-based mixing patterns among PWID in North America.

$$\mathbf{M}_g = \begin{bmatrix} g_{11} & g_{12} \\ g_{21} & g_{22} \end{bmatrix} = \begin{bmatrix} 0.512 & 0.488 \\ 0.382 & 0.618 \end{bmatrix} \quad (3)$$

Incarceration dynamics

Incarceration dynamics are modelled as transitions between community and prison (Fig. S1.2(a)). People initiate IDU and

are assumed to have never been incarcerated ($P_0(t)$) (Borquez et al., 2018; Stone et al., 2017; Leclerc et al., 2018). They can then experience a first incarceration at a time-dependent rate $\eta_0(t)$. This rate was derived from survey data as well as data from correctional services. The overall rate of incarceration was estimated from the size of the incarcerated population ($P_1(t)$) relative to the number of new admissions in the prison system and the size of the population of PWID in the community during the prior year ($N_{pwid}(t-1)$). This population have either experienced (p_{ever}) or not the prison system and people with experience have a higher rate of (re)incarceration (Γ). The overall rate of incarceration can thus be calculated as follows.

$$P_1(t) = \eta_0(t) ((1 - p_{ever}) + \Gamma p_{ever}) N_{pwid}(t-1)$$

$$\Leftrightarrow \eta_0(t) = \frac{P_1(t)}{((1 - p_{ever}) + \Gamma p_{ever}) N_{pwid}(t-1)}$$

Incarcerated individuals are released at a time-dependent rate $\eta_1(t) = 1/D_{P_1}(t)$, where $D_{P_1}(t)$ is the average duration of time spent in prison per incarceration, collected from correctional data. This definition was used because sentence lengths could overestimate time spent in prison per year, and thus underestimate the release rate. In most provincial prisons, people spend less time per incarceration than their sentence prescribes because of good behaviours and/or overcrowding. (Chéné, 2014; Courtemanche et al., 2016).

The literature on mortality and risk of HCV acquisition shows an increased risk for individuals recently released from prison (Mathers et al., 2013; Stone et al., 2018). The model therefore differentiates between recently released and previously released individuals (Borquez et al., 2018). Upon release, and for the following 6 months, individuals are considered at a higher risk of HCV acquisition, transmission, and drug-related mortality (P_2). After 6 months ($\eta_2 = 1/2$), they transition to the previously released compartment (P_3) where they are subject to the same mortality and HCV acquisition risk as the never incarcerated individuals. The reincarceration rate is the same for all individuals with experience of the prison system (recently or previously), and is equal to the rate of incarceration multiplied by a rate ratio computed from prison surveys (Courtemanche et al., 2016; Poulin et al., 2007). The system of ordinary differential equations describing incarceration dynamics is defined below.

$$\begin{aligned} \frac{dP_0(t)}{dt} &= \theta(t) - \eta_0(t)P_0(t) \\ \frac{dP_1(t)}{dt} &= \eta_0(t)P_0(t) + \eta_3(t)(P_2(t) + P_3(t)) - \eta_1 P_1(t) \\ \frac{dP_2(t)}{dt} &= \eta_1 P_1(t) - (\eta_2 + \eta_3(t))P_2(t) \\ \frac{dP_3(t)}{dt} &= \eta_2 P_2(t) - \eta_3(t)P_3(t) \end{aligned} \quad (4)$$

Injection dynamics

Injection dynamics describe how PWID cease to inject or initiate (and stop) OAT (Figure S1.2). Briefly, active PWID

($I_0(t)$) cease to inject at a rate δ_0 . This rate is computed as the inverse length of an individual's injecting career, which can vary between 5 and 23 years (Montain et al., 2016). We chose a wide range, because there is a lot of uncertainty regarding the duration of injecting drug use. Once in the ex-PWID compartment ($I_1(t)$), these individuals do not contribute to HCV transmission, as they have no injecting risk behaviors and cannot re-initiate injection. Otherwise, PWID can initiate OAT ($O(t)$) at a rate δ_1 , which was estimated from the average yearly OAT coverage in SurvUDI. Once on OAT, people are allowed to continue injection, albeit at a reduced rate. This assumption is justified when modelling the Montréal epidemic, which is driven by cocaine and where poly-injecting drug use is frequent. Thus, OAT is often not sufficient to reduce injecting risk behaviors if people inject other substances. After one year, a proportion ϵ transitions back to active injection, while the rest stays on OAT. This is the retention rate of OAT, and was estimated from a meta-analysis (Bao et al., 2009). People can remain on OAT until they stop injecting completely, which is simply the same injecting career length parameter as before. Being on OAT reduces the risk of HCV transmission and acquisition by half, as was stated in a recent meta-analysis (Platt et al., 2017).

$$\begin{aligned} \frac{dI_0(t)}{dt} &= \theta(t) + \epsilon(t)O(t) - (\delta_0 + \delta_1)I_0(t) \\ \frac{dI_1(t)}{dt} &= \delta_0(I_0(t) + O(t)) \\ \frac{dO(t)}{dt} &= \delta_1 I_0(t) - (\epsilon + \delta_0)O(t) \end{aligned} \quad (5)$$




Figure S1.2: (a) People who initiate injection have never been incarcerated ($P_0(t)$) and can be incarcerated at a time-dependent rate $\eta_0(t)$. They are then released back to the community at a time-dependent rate $\eta_1(t)$ and are considered recently released for 6 months ($P_2(t)$) after which they become previously released ($P_3(t)$). People with experience in the prison system can be reincarcerated at a rate $\eta_3(t)$. (b) People who inject drugs (PWID, $I_0(t)$) completely stop injecting at a rate which is defined as the inverse of the average injecting duration (δ_0). They can also initiate OAT at a constant rate δ_1 . On OAT, people can continue injecting and only stop after the average duration of injection δ_0 . Once people have stopped they cannot go back to injecting.

Model parametrization

Data

Two major sources of data were used to inform parameters for this study: repeated cross-sectional surveys of PWID in Montréal (SurvUDI, 2003-2015) and two large prison surveys conducted in 7 of the 17 provincial prisons in Québec (in 2003 and 2014) (Leclerc et al., 2018; Poulin et al., 2007; Courtemanche et al., 2018). These two data sources are further detailed below. Parameters that could not be estimated from these local surveys were obtained from the relevant peer-reviewed literature. Where data was not available from meta-analyses, the most robust studies to inform model parameters were used.

SurvUDI

SurvUDI is a surveillance network of PWID in the province of Québec as well as in the city of Ottawa, and was first established in 1995 (Leclerc et al., 2018). It was then associated with the pan-Canadian I-track survey. It is designed as repeated cross-sectional bio-behavioural surveys and recruitment is multi-settings, occurring both in NSP, fixed-sites, and community outreach activities. As such SurvUDI uses a convenience sampling design, and all sites working in collaboration with the SurvUDI network have their own sampling procedure. For instance, at *Cactus Montréal*, one of the main recruiting site in Montréal, recruitment happens continuously on a fixed schedule (Leclerc et al., 2018). Over the whole history of the network, 1,509 women and 4,835 men participated in the study in Montréal and a total of 13,286 survey questionnaires were completed. Re-surveyed participants were used to assess longitudinal outcomes such as incidence. Prevalence was defined as the prevalence of HCV at the first lifetime visit in the network, such that individuals could contribute to more than one year but not twice in the same year (Leclerc et al., 2018). This survey provides information on a wide range of parameters and outcomes. All data from these surveys were abstracted from official reports produced by the *Institut national de la santé publique du Québec* (INSPQ). Because of the convenience sampling approach, a design effect was used to account for a potentially greater uncertainty around point estimates. A design effect of 2 was applied to all uncertainty estimates in SurvUDI, which is standard in studies targeting hidden populations, as no value was provided for SurvUDI (Salganik, 2006; Wejnert et al., 2012).

Prison Survey

Two cross-sectional bio-behavioural surveys were conducted in prison settings in 2003 and 2014 (Poulin et al., 2007; Courtemanche et al., 2018). The first survey was performed in 7 of the 17 provincial prisons in Québec, representing about half of the prison population and collected information on 1607 participants. One male prison (Bordeaux or *Établissement de détention de Montréal*) and one female prison (Maison Tanguay) were located in Montréal. The second survey, conducted in 2014, was performed in the same 7 prisons that participated in 2003 and used a comparable survey methodology and instruments to collect information on 1581 participants. People could not participate more than once in the surveys. The research team were

granted access to the microdata from the survey and performed secondary analyses to inform a wealth of parameters.

Model calibration

The objective of model calibration is to reproduce temporal trends in relevant epidemiological outcomes using statistical techniques that select the best combinations of parameters. The epidemiological outcomes used in model calibration are informed by both SurvUDI and the two prison surveys. Because SurvUDI is repeated annually at the same recruitment sites, it is possible to uniquely identify participants and estimate HCV incidence in the network from 2003 to 2014. As this incidence only measures new antibody positive cases, it cannot account for reinfections (Leclerc et al., 2018). The model was also calibrated to antibody prevalence among incarcerated individuals self-reporting IDU in the past six months in 2014. For the 2003 survey, prevalence among people with IDU in the past six months is extrapolated by applying the observed prevalence ratio in people with a history of IDU to recent IDU of the 2014 survey (Courtemanche et al., 2018; Poulin et al., 2007).

Given its flexibility, a Bayesian framework was adopted for model calibration and appropriate prior distributions were elicited. More specifically, a sampling importance resampling algorithm was used to approximate the posterior distributions of model outcomes. Using this algorithm 120,000 parameter sets were first sampled from their prior distributions using Latin hypercube sampling, a technique which allows a good exploration of the whole parameter space. For each parameter sets, the model was first run for 75 years using baseline parameter values from 2003 so that endemic equilibrium could be reached before the start of the epidemic simulations. Then, the model was run from 2003 to 2015 and yearly prevalence and incidence were calculated for the relevant population stratification (prison or community). The likelihood of each parameter set was then calculated for the prevalence and incidence outcomes. The overall model likelihood was obtained by summing the log-likelihood of the model outcomes.

$$\log(\mathcal{L}) = \log(\mathcal{L}_{prev}^c) + \log(\mathcal{L}_{prev}^p) + \log(\mathcal{L}_{inci})$$

Where \mathcal{L}_{prev}^c is the binomial likelihood for prevalence in the community over the time interval from $t = 2003$ to $t = 2014$ for the yearly survey of sample size n_t^c , with x_t^c prevalent cases, and the estimated model prevalence during that year p_t^c .

$$\log(\mathcal{L}_{prev}^c) = \sum_{t=2003}^{2014} \log \binom{n_t^c}{x_t^c} + x_t^c \log(p_t^c) + (n_t^c - x_t^c) \log(1 - p_t^c)$$

In prison the likelihood (\mathcal{L}_{prev}^p) has an identical structure except for the fact that there are only two surveys (2003, 2014).

$$\log(\mathcal{L}_{prev}^p) = \sum_{t \in \{2003, 2014\}} \log \binom{n_t^p}{x_t^p} + x_t^p \log(p_t^p) + (n_t^p - x_t^p) \log(1 - p_t^p)$$

Incidence in the community follows a Poisson likelihood \mathcal{L}_{inci} over the same interval. With the sample size of the survey at a given year n_t^c , with x_t^c new cases observed in that survey, the estimated model incidence $\lambda'(t)$, and a constant K .

$$\log(\mathcal{L}_{inci}) = \sum_{t=2003}^{2014} (-n_t^c \lambda_t^c + \log(\lambda_t^c) x_t^c - K)$$

Finally, the posterior distributions of the quantities of interest were obtained by sampling with replacement 1163 parameter sets proportionally to their likelihood weight. The weights are defined as below for parameter set i

$$w_i = \frac{e^{\log(\mathcal{L}_i) - \log(\mathcal{L}_{max})}}{\sum_{i=1}^n e^{\log(\mathcal{L}_i) - \log(\mathcal{L}_{max})}}$$

This procedure allows the selection of parameter sets that have the greatest concordance to the empirical data and to propagate parameter uncertainty to the model's predictions. To ensure that the model was reliable, cross-validation of model predictions for HCV status awareness, and both background, and HCV-related mortality was performed. The ordinary differential equations system was implemented in Python 3.6 and solved with a validated Runge-Kutta algorithm of the 4th order from the SciPy module.

References

Bao, Y.P., Liu, Z.M., Epstein, D.H., Du, C., Shi, J., Lu, L., 2009. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. *The American journal of drug and alcohol abuse* 35, 28–33. URL: <https://www.ncbi.nlm.nih.gov/pubmed/19152203>, doi:10.1080/00952990802342899.

Borquez, A., Beletsky, L., Nosyk, B., Strathdee, S.A., Madrazo, A., Abramovitz, D., Rafful, C., Morales, M., Cepeda, J., Panagiotoglou, D., Krebs, E., Vickerman, P., Claude Boily, M., Thomson, N., Martin, N.K., 2018. The effect of public health-oriented drug law reform on hiv incidence in people who inject drugs in tijuana, mexico: an epidemic modelling study. *The Lancet. Public health* 3, e429–e437. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30122559>, doi:10.1016/S2468-2667(18)30097-5.

Chéné, B., 2014. Statistiques correctionnelles 2012-2013, Québec. Technical Report. Services correctionnels, ministère de la Sécurité publique.

Courtemanche, Y., Poulin, C., Serhir, B., Alary, M., 2018. Hiv and hepatitis c virus infections in quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. *Canadian Journal of Public Health* 109, 353–361. URL: <https://doi.org/10.17269/s41997-018-0047-4>, doi:10.17269/s41997-018-0047-4.

Courtemanche, Y., et al., 2016. Étude de prévalence du VIH et du VHC chez les personnes incarcérées dans les établissements de détention provinciaux du Québec. Technical Report. Centre de recherche du CHU de Québec.

Erman, A., Hansen, T., Bielecki, J.M., Feld, J., Krahn, M.D., Thein, R., 2018. A160 estimation of fibrosis progression rates for chronic hepatitis c: Updated meta-analysis and meta-regression. *Journal of the Canadian Association of Gastroenterology* 1, 276–277. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507931/>, doi:10.1093/jcag/gwy008.161.

Feld, J.J., Foster, G.R., 2016. Second generation direct-acting antivirals – do we expect major improvements? *Journal of Hepatology* 65, S130–S142. URL: <https://doi.org/10.1016/j.jhep.2016.07.007>, doi:10.1016/j.jhep.2016.07.007.

Leclerc, P., Vandal, A.C., Fall, A., Bruneau, J., Roy, É., Brissette, S., Archibald, C., Arruda, N., Morissette, C., 2014. Estimating the size of the population of persons who inject drugs in the island of montréal, canada, using a six-source capture–recapture model. *Drug and Alcohol Dependence* 142, 174–180. URL: <http://www.sciencedirect.com/science/article/pii/S0376871614009442>, doi:https://doi.org/10.1016/j.drugalcdep.2014.06.022.

Leclerc, P., et al., 2018. Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection : épidémiologie du VIH de 1995 à 2016 et épidémiologie du VHC de 2003 à 2016. Technical Report. Institut national de santé publique du Québec.

Mathers, B.M., Degenhardt, L., Bucello, C., Lemon, J., Wiessing, L., Hickman, M., 2013. Mortality among people who inject drugs: a systematic review and meta-analysis. *Bulletin of the World Health Organization* 91, 102–123. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23554523>, doi:10.2471/BLT.12.108282.

Montain, J., Ti, L., Hayashi, K., Nguyen, P., Wood, E., Kerr, T., 2016. Impact of length of injecting career on hiv incidence among people who inject drugs. *Addictive behaviors* 58, 90–94. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26921723>, doi:10.1016/j.addbeh.2016.02.020.

Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., Maher, L., Palmateer, N., Taylor, A., Bruneau, J., Hickman, M., 2017. Needle syringe programmes and opioid substitution therapy for preventing hepatitis c transmission in people who inject drugs. The Cochrane database of systematic reviews 9, CD012021–CD012021. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28922449>, doi:10.1002/14651858.CD012021.pub2.

Poulin, C., Alary, M., Lambert, G., Godin, G., Landry, S., Gagnon, H., Demers, E., Morarescu, E., Rochefort, J., Claessens, C., 2007. Prevalence of hiv and hepatitis c virus infections among inmates of quebec provincial prisons. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 177, 252–256. URL: <https://www.ncbi.nlm.nih.gov/pubmed/17664448>, doi:10.1503/cmaj.060760.

Sacks-Davis, R., Grebely, J., Dore, G.J., Osburn, W., Cox, A.L., Rice, T.M., Spelman, T., Bruneau, J., Prins, M., Kim, A.Y., McGovern, B.H., Shoukry, N.H., Schinkel, J., Allen, T.M., Morris, M., Hajarizadeh, B., Maher, L., Lloyd, A.R., Page, K., Hellard, M., study group, I., 2015. Hepatitis c virus reinfection and spontaneous clearance of reinfection—the inc3 study. *The Journal of infectious diseases* 212, 1407–1419. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25883387>, doi:10.1093/infdis/jiv220.

Salganik, M.J., 2006. Variance estimation, design effects, and sample size calculations for respondent-driven sampling. *Journal of urban health : bulletin of the New York Academy of Medicine* 83, i98–i112. URL: <https://www.ncbi.nlm.nih.gov/pubmed/16937083>, doi:10.1007/s11524-006-9106-x.

Shah, H., Bilodeau, M., Burak, K.W., Cooper, C., Klein, M., Ramji, A., Smyth, D., Feld, J.J., 2018. The management of chronic hepatitis c: 2018 guideline update from the canadian association for the study of the liver. *Canadian Medical Association Journal* 190, E677. URL: <http://www.cmaj.ca/content/190/22/E677.abstract>, doi:10.1503/cmaj.170453.

Smith, D.J., Jordan, A.E., Frank, M., Hagan, H., 2016. Spontaneous viral clearance of hepatitis c virus (hcv) infection among people who inject drugs (pwid) and hiv-positive men who have sex with men (hiv+msm): a systematic review and meta-analysis. *BMC infectious diseases* 16, 471–471. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27595855>, doi:10.1186/s12879-016-1807-5.

Stone, J., Fraser, H., Lim, A.G., Walker, J.G., Ward, Z., MacGregor, L., Trickey, A., Abbott, S., Strathdee, S.A., Abramovitz, D., Maher, L., Iversen, J., Bruneau, J., Zang, G., Garfein, R.S., Yen, Y.F., Azim, T., Mehta, S.H., Milloy, M.J., Hellard, M.E., Sacks-Davis, R., Dietze, P.M., Aitken, C., Aladashvili, M., Tsertsvadze, T., Mravčik, V., Alary, M., Roy, E., Smyrnov, P., Sazonova, Y., Young, A.M., Havens, J.R., Hope, V.D., Desai, M., Heinsbroek, E., Hutchinson, S.J., Palmateer, N.E., McAuley, A., Platt, L., Martin, N.K., Altice, F.L., Hickman, M., Vickerman, P., 2018. Incarceration history and risk of hiv and hepatitis c virus acquisition among people who inject drugs: a systematic review and meta-analysis. *The Lancet. Infectious diseases* 18, 1397–1409. URL: <https://www.ncbi.nlm.nih.gov/pubmed/30385157> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280039/>, doi:10.1016/S1473-3099(18)30469-9.

Stone, J., Martin, N.K., Hickman, M., Hutchinson, S.J., Aspinall, E., Taylor, A., Munro, A., Dunleavy, K., Peters, E., Bramley, P., Hayes, P.C., Goldberg, D.J., Vickerman, P., 2017. Modelling the impact of incarceration and prison-based hepatitis c virus (hcv) treatment on hcv transmission among people who inject drugs in scotland. *Addiction (Abingdon, England)* 112, 1302–1314. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28257600>, doi:10.1111/add.13783.

Wejnert, C., Pham, H., Krishna, N., Le, B., DiNenno, E., 2012. Estimating design effect and calculating sample size for respondent-driven sampling

studies of injection drug users in the united states. *AIDS and behavior* 16, 797–806. URL: <https://www.ncbi.nlm.nih.gov/pubmed/22350828>, doi:10.1007/s10461-012-0147-8.